Cellectis SA Advances CAR T-cell Therapy for Solid Tumors

Cellectis SA (CLLS) has released an update.

Cellectis SA is showcasing its innovative strategies to improve the effectiveness of CAR T-cell therapies against solid tumors at the Society for Immunotherapy of Cancer’s Annual Meeting. By using TALEN-mediated gene editing, Cellectis aims to enhance the efficacy of these therapies while minimizing potential toxicities, offering hope for patients with challenging malignancies. This development underscores the company’s commitment to advancing cancer treatment with cutting-edge biotechnology.

For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.